Biomarker Use in Patients on Active Surveillance

The panel explores the role of biomarkers in monitoring disease progression for prostate cancer patients on active surveillance, discussing how these tests aid in detecting changes that may warrant intervention.

EP: 1.Overview of Prostate Cancer

EP: 2.Challenges of PSA as a Diagnostic Biomarker

EP: 3.Role of Biomarker and Genetic Testing in Prostate Cancer Diagnosis

EP: 4.Emerging Serum, Urine, and Tissue Biomarkers in the Clinical Setting

EP: 5.High Risk Populations in the Development of Prostate Cancer

EP: 6.Risk Stratification in Prostate Cancer Patients

EP: 7.Challenges in Risk Assessment and Biomarkers in Treatment Recommendations

EP: 8.Influences and Challenges of Biomarkers on Treatment Selection

EP: 9.Efficacy of Biomarker Test Results

Now Viewing

EP: 10.Biomarker Use in Patients on Active Surveillance

EP: 11.Use of Molecular Biomarkers Tests

EP: 12.Integrating Biomarker Testing Into the Patient Care Journey

EP: 13.AI and the Future of Biomarkers in Prostate Cancer

EP: 14.Current Advancements in Biomarker Research

EP: 15.Unmet Needs and Treatment Gaps in Prostate Cancer

EP: 16.Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer

EP: 17.Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing

EP: 18.Tim Richardson, MD, on genetic testing in the era of targeted therapies

EP: 19.Paul Sieber, MD, on the future of genetic testing in prostate cancer

Video content above is prompted by the following question:

• For patients on active surveillance, how do you use biomarkers?

Related Videos

Related Content

Advertisement

January 30th 2025

MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine

Hannah Clarke

“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 27th 2025

Black men cite lack of invitation, information as key barriers to prostate cancer trials

Hannah Clarke

According to the authors, these findings highlight the need to more effectively include Black men in prostate cancer research.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

Related Content

Advertisement

January 30th 2025

MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine

Hannah Clarke

“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 27th 2025

Black men cite lack of invitation, information as key barriers to prostate cancer trials

Hannah Clarke

According to the authors, these findings highlight the need to more effectively include Black men in prostate cancer research.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.